opucolimab (HLX20)
/ Fosun Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 03, 2022
A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=26 | Completed | Sponsor: Shanghai Henlius Biotech | Recruiting ➔ Completed
Trial completion • Cervical Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1